ArticleOncoTargets and therapy2016
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.
Ahmed O Kaseb et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this paperpooled itcites it